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Abstract
Background: Liver stiffness measurement (LSM) using transient elastography (FibroScanH) can assess liver fibrosis
noninvasively. This study investigated whether LSM can predict the development of liver-related events (LREs) in chronic
hepatitis B (CHB) patients showing histologically advanced liver fibrosis.
Methods: Between March 2006 and April 2010, 128 CHB patients with who underwent LSM and liver biopsy (LB) before
starting nucleot(s)ide analogues and showed histologically advanced fibrosis ($F3) with a high viral loads [HBV DNA
$2,000 IU/mL] were enrolled. All patients were followed regularly to detect LRE development, including hepatic
decompensation (variceal bleeding, ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal
syndrome) and hepatocellular carcinoma (HCC).
Results: The mean age of the patient (72 men, 56 women) was 52.2 years. During the median follow-up period [median 27.8
(12.6–61.6) months], LREs developed in 19 (14.8%) patients (five with hepatic decompensation, 13 with HCC, one with both).
Together with age, multivariate analysis identified LSM as an independent predictor of LRE development [P,0.044; hazard
ratio (HR), 1.038; 95% confidence interval (CI), 1.002–1.081]. When the study population was stratified into two groups using
the optimal cutoff value (19 kPa), which maximized the sum of sensitivity (61.1%) and specificity (86.2%) from a time-
dependent receiver operating characteristic curve, patients with LSM.19 kPa were at significantly greater risk than those
with LSM#19 kPa for LRE development (HR, 7.176; 95% CI, 2.257–22.812; P=0.001).
Conclusion: LSM can be a useful predictor of LRE development in CHB patients showing histologically advanced liver
fibrosis.
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Introduction
Chronic infection with hepatotropic viruses is the main cause of
chronic liver disease (CLD) worldwide, and hepatitis B virus
(HBV) is predominant in the Far East [1,2]. Approximately 10–
20% of patients with chronic hepatitis B (CHB) infection have liver
cirrhosis at first presentation, and an additional 20–30% of
patients will eventually develop this condition and its complica-
tions within one or more decades [3,4]. Previous studies indicated
an annual risk of developing hepatocellular carcinoma (HCC) of
1–6%, and a similar or higher risk of hepatic decompensation after
the development of cirrhosis [5,6]. Although antiviral treatment
using nucleot(s)ide analogues (NUCs) suppresses HBV effectively
[7], liver-related events (LREs) including hepatic decompensation,
HCC, and liver-related death still occur and remain an important
watershed in the management algorithm of patients with CHB.
Because LREs usually develop in patients with advanced liver
fibrosis and cirrhosis, the early detection of advanced liver fibrosis
and cirrhosis and the assessment of their severity for the design of
optimal surveillance and intervention strategies are important.
Although liver biopsy (LB) has been the gold standard for assessing
liver fibrosis to date [8], it is prone to sampling error and
interpretational variability [9]. Recently, liver stiffness measure-
ment (LSM) using transient elastography (FibroScanH) has been
introduced for assessing liver fibrosis with accurate, reproducible,
and reliable results [10,11]. Furthermore, because LSM can be
expressed numerically as a continuous variable, clinicians can
grade the degree of liver fibrosis, even in patients with cirrhosis,
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HCC [12–14]. Thus, we hypothesized that LSM could predict the
development of LREs in CHB patients who were receiving
antiviral treatment using NUCs due to histologically advanced
liver fibrosis or cirrhosis with a high viral load.
Previous cross-sectional studies have reported an association
between LSM and the presence of liver-related complications or
HCC in patients with CLD [12,13,15,16]. However, few
prospective longitudinal studies have investigated the role of
LSM as a predictor of LRE development in patients with
advanced liver fibrosis. Thus, we evaluated the usefulness of
LSM in assessing the risk of LRE development in CHB patients
showing histologically advanced liver fibrosis with a high viral
load.
Methods
Patients
Between March 2006 and April 2010, a total of 178 NUC-naı ¨ve
CHB patients underwent LB to assess the degree of liver fibrosis
and necroinflammation before starting antiviral treatment at
Severance Hospital, Yonsei University College of Medicine, Seoul,
Korea. CHB was defined as the persistent presence of serum
hepatitis B surface antigen (HBsAg) for more than 6 months and
HBV DNA positivity on a polymerase chain reaction (PCR) assay.
Patients who provided written informed consent and received LB
and LSM were consecutively enrolled in this prospective study.
The study protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki and was approved by the institutional
review board of Severance Hospital.
Exclusion criteria were as follows: 1) LSM failure (no valid shots;
n=0), 2) invalid LSM [defined as an interquartile range (IQR) to
median value ratio (IQR/M) .0.3, success rate ,60%, or ,10
valid measurements; n=6] [17], 3) a history of hepatic de-
compensation or antiviral treatment (n=0), 4) co-infection with
hepatitis C, hepatitis D, or HIV (n=1), 5) heavy alcohol
consumption (.30 g/day for .5 years; n=4), 6) right-sided heart
failure, ascites, or pregnancy (n=0), 7) F0–2 fibrosis stage on LB
(n=20), 8) low viral load (,2,000 IU/mL; n=7), 9) LB specimen
shorter than 15 mm (n=9), and 10) follow-up loss (n=3)(Figure
S1).
A total of 50 patients were excluded; the remaining 128 CHB
patients showing advanced ($F3) liver fibrosis on LB with a high
viral load (HBV DNA $2,000 IU/L) were selected for the final
statistical analysis (Figure S1).
Laboratory tests
On the same day as LB and LSM, blood parameters including
serum albumin, total bilirubin, alanine aminotransferase (ALT),
prothrombin time, platelet count, and alpha-fetoprotein (AFP)
were recorded. HBsAg and hepatitis B e antigen (HBeAg) were
measured using standard enzyme-linked immunosorbent assays
(Abbott Diagnostics, Abbott Park, IL, USA). HBV DNA levels
were measured by quantitative PCR assay (Amplicor HBV
Monitor Test; Roche Diagnostics, Basel, Switzerland) with
a detection limit of 12 IU/mL. The upper normal range of
ALT was 40 IU/L.
Liver stiffness measurement
On the same day as LB, LSM was performed on the right lobe
of the liver through the intercostal spaces on patients lying in the
dorsal decubitus position with the right arm in maximal abduction
[17]. One experienced technician (.10,000 examinations) who
was blinded to the patients’ clinical data performed all LSMs. The
Table 1. Baseline Characteristics (n=128).
Variables Values
Demographic data
Age (years) 52.269.3
Male 72 (56.3)
Diabetes mellitus 11 (8.6)
Body mass index (kg/m
2) 24.062.9
Laboratory data
Serum albumin (g/dL) 4.260.5
Total bilirubin (mg/dL) 0.860.3
Alanine aminotransferase (IU/L) 44.4621.6
Prothrombin time (%) 90.969.8
Platelet count (10
9/L) 148.5648.4
Alpha-fetoprotein (ng/mL) 4.7 (0.8–50.6)
Histological data
Fibrosis stage, 3/4 18 (14.1)/110 (85.9)
Activity grade, 1–2/3–4 97 (75.8)/31 (24.2)
Liver stiffness measurement
LSM values (kPa) 12.9 (4.4–57.1)
Success rate (%) 100 (63–100)
Interquartile range/median value (kPa) 0.15 (0.01–0.30)
Antiviral agent
Lamivudine 49 (38.3)
Entecavir 79 (61.7)
Variables are expressed as mean 6 SD, median (range), or n (%).
HBeAg, hepatitis B e antigen; LSM, liver stiffness measurement; kPa, kilopascal.
doi:10.1371/journal.pone.0036676.t001
Figure 1. The cumulative incidence rates of LREs (Kaplan-Meier
plot). The cumulative incidence rates of LREs at 1, 2, and 3 years were
3.1%, 11.7%, and 16.2%, respectively. LRE, liver-related event.
doi:10.1371/journal.pone.0036676.g001
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measurements by the total number of measurements. IQR was
defined as an index of intrinsic variability of LSM corresponding
to the interval of LSM results containing 50% of the valid
measurements between the 25th and 75th percentiles [14]. LSM
scores are expressed as kilopascals (kPa). When LSM showed an
IQR/M .0.3, success rate ,60%, or ,10 valid measurements, it
was regarded as invalid and was excluded from the final analysis.
Liver biopsy and liver histology evaluation
LB specimens were fixed in formalin and embedded in paraffin.
Four-micrometer-thick sections were stained with hematoxylin &
eosin and Masson’s trichrome. All liver tissue samples were
evaluated by an experienced hepatopathologist who was blinded
to the clinical data of the study population, including LSM results.
Liver fibrosis and necroinflammation were evaluated semiquanti-
tatively according to the Batts scoring system [18]. Fibrosis was
staged on a 0–4 scale: F0, no fibrosis; F1, portal fibrosis; F2,
periportal fibrosis; F3, septal fibrosis; and F4, cirrhosis. The
activity grade referred to the degree of hepatocellular necroin-
flammatory activity: A0, no activity; A1, minimal; A2, mild; A3,
moderate; and A4, severe activity. Steatosis in the liver specimen
was graded on a four-point scale: S0 (non-significant, ,5%), S1
(mild, 5–33%), S2 (moderate, 34–66%) and S3 (severe, $66% of
hepatocytes with fat deposits) [19]. LB specimens shorter than
15 mm were considered ineligible and excluded from the final
analysis. The median length of LB specimens was 17 mm (range,
15–23 mm).
Follow up
All patients underwent LB and LSM and were screened
ultrasonographically for HCC at their initial visit. NUCs, such
as lamivudine and entecavir, were chosen non-randomly after
enrollment according to the patient’s economic status and
physicians’ judgment, and an HCC surveillance program was
initiated in all patients. Patients were followed up with AFP and
ultrasonography every 3 or 6 months. Furthermore, patients were
assessed at baseline and every 3 months thereafter for clinical
evidence of hepatic decompensation, including variceal bleeding,
ascites, hepatic encephalopathy (HE), spontaneous bacterial
Table 2. Comparison Between Patients with and without LRE Development.
Variables
Patients with LRE
development
(n=19, 14.8%)
Patients without LRE
development
(n=109, 85.2%) P value
Demographic data
Age (years) 56.266.5 51.569.6 0.043
Male 12 (63.2) 60 (55.0) 0.511
Diabetes mellitus 3 (15.8) 8 (7.3) 0.210
Body mass index (kg/m
2) 24.162.9 23.962.9 0.794
HBeAg positivity 12 (63.2) 58 (53.2) 0.422
HBV DNA (log10 IU/mL) 5.761.1 5.661.2 0.610
Laboratory data
Serum albumin (g/dL) 3.960.6 4.360.4 0.003
Total bilirubin (mg/dL) 0.960.3 0.860.3 0.181
Alanine aminotransferase (IU/L) 39.4616.0 45.3622.4 0.279
Prothrombin time (%) 85.1612.7 91.969.0 0.037
Platelet count (10
9/L) 124.7637.4 152.7649.0 0.019
Alpha-fetoprotein (ng/mL) 6.7 (2.4–38.2) 4.4 (0.8–50.6) 0.020
Histological data
Fibrosis stage, 3/4 4 (21.1)/15 (78.9) 14 (12.8)/95 (87.2) 0.342
Activity grade, 1–2/3–4 12 (63.2)/7 (36.8) 85 (78.0)/24 (22.0) 0.164
Liver stiffness measurement
LSM values (kPa) 21.1 (7.8–57.1) 11.8 (4.4–48.0) 0.011
Antiviral treatment
Antiviral agent 0.515
Lamivudine 6 (31.6) 43 (39.4)
Entecavir 13 (68.4) 66 (60.6)
HBV DNA negativity
At 3 months 10 (52.6) 67 (61.5) 0.468
At 6 months 13 (68.4) 80 (73.4) 0.654
At 12 months 15 (78.9) 92 (84.4) 0.515
YMDD mutation 2(10.5) 15(13.8) 1.000
Variables are expressed as mean 6 SD, median (range), or n (%).
LRE, liver-related event; HBeAg, hepatitis B e antigen; LSM, liver stiffness measurement; kPa, kilopascal.
doi:10.1371/journal.pone.0036676.t002
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the follow-up period (March 2011), one patient had died due to
HCC and another had undergone liver transplantation after
ascitic decompensation.
Primary endpoint
The primary endpoint was the development of LREs, including
hepatic decompensation (variceal bleeding, ascites, HE, SBP, and
HRS) and HCC.
Definition of hepatic decompensation
Variceal bleeding was diagnosed endoscopically if hemorrhage
from the dilated veins in the distal esophagus or proximal stomach
caused by elevated pressure in the portal venous system was noted
[20]. Ascites was diagnosed by imaging, such as computed
tomography (CT) or ultrasonography, if fluid collection within
the abdominal cavity associated with cirrhosis was noted [21]. HE
was diagnosed if confusion, altered level of consciousness, and
coma developed as a result of liver failure, after the exclusion of
known brain disease [22]. SBP was defined as an ascitic fluid
infection without an intra-abdominal, surgically treatable source
[23]. Diagnosis was established by a positive ascitic fluid bacterial
culture and an elevated ascitic fluid absolute polymorphonuclear
leukocyte count ($250 cells/mm3). HRS was diagnosed when
acute renal failure developed in association with advanced chronic
liver disease, after the exclusion of other causes of renal failure
[24].
Diagnosis of HCC
HCC was diagnosed based on the guidelines of the American
Association for the Study of Liver Diseases (AASLD) [25]. Briefly,
patients were diagnosed with HCC if they had a tumor with
a maximum diameter .2 cm, features typical of HCC on
dynamic CT (hyperattenuation in the arterial phase and early
washout in the portal phase), and AFP .200 ng/mL. If the
maximum diameter of the tumor was 1–2 cm, dynamic CT and
magnetic resonance imaging were performed and HCC was
diagnosed if coincidental typical features of HCC were noted. If
the tumor did not satisfy the above criteria, a biopsy was
performed. When the tumor was ,1 cm, ultrasonographic
examination was repeated after 3 months.
Statistical analyses
Data are expressed as the mean 6 standard deviation (SD),
median (range), or n (%), as appropriate. Baseline characteristics of
patients with and without LRE development were compared using
the chi-squared and Fisher’s exact tests. To identify independent
predictors of LRE development, univariate and subsequent
multivariate Cox proportional hazard regression analyses were
used. Hazard ratios (HRs) and corresponding 95% confidence
intervals (CIs) are indicated. Time-dependent receiver operating
characteristic (ROC) curves and areas under the ROC (AUROC)
were used to calculate the optimal LSM cutoff value for the
prediction of LRE development, which maximized the sum of
sensitivity and specificity. The annual incidence rates of HCC
were expressed in person-years. The cumulative incidence rates of
HCC were calculated using the Kaplan–Meier method. A P
value,0.05 on a two-tailed test was considered statistically
significant. Statistical analyses were performed using SPSS
software (ver. 18.0; SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
The baseline characteristics of 128 patients at enrollment are
summarized in Table 1. The mean age of the patients (72 men
and 56 women) was 52.2 years. All patients with cirrhosis showed
preserved liver function of Child–Pugh class A. The mean body
mass index (BMI) and ALT were 24.0 kg/m
2 and 44.4 IU/L,
respectively, and the median LSM value was 12.9 kPa.
F3 and F4 fibrosis stages were noted in 18 (14.1%) and 110
(85.9%) patients, respectively, and most patients (n=97, 75.8%)
had a necroinflammatory activity grade of 1–2 (Table 1). S0–1
steatosis was identified in 127 (99.2%) patients and S2 in one
(0.8%), whereas none showed S3 steatosis.
LRE development and comparisons between patients
with and without LREs
During the follow-up period [median, 27.8 (range, 12.6–61.6)
months] constituting a total of 297 person-years, LREs developed
in 19 (14.8%) patients (6.4/100 person-years; five cases with
decompensation, 13 with HCC, and one with both decompensa-
tion and HCC; Table 2). The six cases of hepatic decompensation
included variceal bleeding in two patients, ascites development in
two, and HE in two. SBP and HRS did not develop during the
follow-up period. The cumulative incidence rates of LREs at 1, 2,
and 3 years were 3.1%, 11.7%, and 16.2%, respectively
(Figure 1). The incidence rate of HCC and hepatic decompen-
sation was 4.7/100 and 2.0/100 person-years, respectively.
When we compared the baseline characteristics of patients with
and without LRE development, serum albumin, prothrombin
time, and platelet count were significantly higher in patients
without LREs, whereas age, AFP, and LSM values were
significantly higher among those with LRE development (all
P,0.05; Table 2). No significant difference was observed in the
proportion of fibrosis stage, activity grade, or steatosis between
patients with and without LRE development (all P.0.05;
Table 2).
Figure 2. Cumulative incidence rates of LREs based on
stratified LSM values (Kaplan-Meier plot). Patients with LSM
value .19 kPa were at a significantly greater risk of LREs development
with a hazard ratio of 7.176 [95% confidence interval, 2.257–22.812;
P=0.001], as compared to those with LSM value #19 kPa. LSM, liver
stiffness measurement; kPa, kilopascal. LRE, liver-related event.
doi:10.1371/journal.pone.0036676.g002
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All patients received antiviral treatment with either lamivudine
(n=49, 38.3%) or entecavir (n=79, 61.7%; Table 1). Baseline
characteristics, including demographic, laboratory, and histologic
data, did not differ between patients who received lamivudine and
those who received entecavir (all P.0.05). Furthermore, the
treatment period until the end of follow-up was similar (median
29.1 months for lamivudine vs. 27.2 months for entecavir;
P=0.785). HBV DNA negativity at 3, 6, and 12 months of
antiviral treatment, type of antiviral agent, and the development of
the YMDD mutation did not influence LRE development (all
P.0.05; Table 2).
Six (12.2%) of the 49 patients treated with lamivudine and 13
(16.5%) patients treated with entecavir developed LREs
(P=0.614). During antiviral treatment, the YMDD mutation
developed in 17 (13.3%) patients who received lamivudine after
a median of 18.5 months; however, no genotypic antiviral
resistance was identified in patients treated with entecavir. Of
the 17 patients with the YMDD mutation, two experienced LRE
development (HCC). Add-on treatment with adefovir was
administered to all patients with the YMDD mutation.
Independent risk factors for LRE development
Together with age, multivariate analysis identified LSM as an
independent predictor of LRE development (P=0.044; HR,
1.038; 95% CI, 1.002–1.081; Table 3). When we used a time-
dependent ROC curve analysis to identify the optimal LSM cutoff
values for stratifying our study population into two groups, 19 kPa
showed the greatest accuracy (AUROC, 0.722; 95% CI, 0.582–
0.864; P=0.003; sensitivity, 61.1%; specificity, 86.2%). Twenty-
seven patients with LSM values .19 kPa were found to be at
a significantly greater risk of LRE development (HR, 7.176; 95%
CI, 2.257–22.812; P=0.001) in comparison with 101 patients with
LSM values #19 kPa (Figure 2).
Incidence of LREs according to fibrosis stage and LSM
values
The median LSM values of patients with F3 and F4 fibrosis
stages were 9.0 (5.7–19.8) kPa and 14.1 (4.4–57.1) kPa,
respectively. LSM values were significantly higher in patients with
F4 fibrosis stage than in those with F3 (10.163.7 vs. 15.868.8 kPa;
P,0.001; Figure 3).
The mean follow-up periods of patients with F3 and F4 fibrosis
stages were similar (24.0 vs. 24.7 months; P=0.827). The
incidence of LREs was similar in patients with F3 and F4 fibrosis
stages (4/18, 22.2% vs. 15/110, 13.6%; P=0.472), whereas it
Table 3. Independent Risk Factors for LRE Development.
Variables Univariate Multivariate
P value Hazard ratio (95% CI) P value
Demographic data
Age 0.045 1.083 (1.008–1.164) 0.030
Male 0.421
Diabetes mellitus 0.192
Body mass index 0.667
Laboratory data
Serum albumin 0.002 0.549 (0.168–1.794) 0.321
Total bilirubin 0.188
Alanine aminotransferase 0.321
Prothrombin time 0.005 0.979 (0.935–1.025) 0.363
Platelet count 0.015 0.996 (0.983–1.009) 0.581
Alpha-fetoprotein 0.041 0.984 (0.907–1.067) 0.694
HBeAg positivity 0.517
HBV DNA 0.623
HBV DNA negativity at 3 months 0.750
Liver biopsy data
Fibrosis stage, 3/4 0.352
Activity grade, 1–2/3–4 0.208
Liver stiffness measurement ,0.001 1.038 (1.002–1.081) 0.044
Antiviral treatment
Lamivudine vs. entecavir 0.442
HBV DNA negativity at 3 months 0.750
HBV DNA negativity at 6 months 0.834
HBV DNA negativity at 12 months 0.681
YMDD mutation 0.522
LRE, liver-related event; CI, confidence interval; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; kPa, kilopascal.
doi:10.1371/journal.pone.0036676.t003
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and those with LSM values .19 kPa (7/101, 6.9% vs. 12/27,
44.4%; P,0.001; Figure 4).
Discordance between baseline LSM value and LRE
development
As shown in Figure 4, discordant results between LSM values
and LRE development were identified in 15/27 (55.6%) patients
who did not experience LRE development despite baseline LSM
values .19 kPa and 7/101 (6.9%) patients who developed LREs
despite LSM values #19 kPa. However, no independent variable
that could predict this discordance between LSM value and LRE
development was identified.
Influence of dynamic LSM changes on LRE development
With the exception of 14 patients without follow-up LSMs
before LRE development, 114 patients underwent a second LSM
before LRE development at a median interval of 13.1 (range, 3.8–
51.6) months. Of these, LREs developed in 10 (8.8%) patients.
To estimate the LRE incidence according to LSM change, we
stratified the patients into three groups as follows: baseline and
follow-up LSM values #19 kPa (n=91), baseline LSM .19 kPa
and follow-up LSM #19 kPa (n=11), and any baseline and
follow-up LSM values .19 kPa (n=12). The overall incidence of
LRE development did not differ among groups (P.0.05).
Although we further stratified the study population [LSM value
increased by .30% of baseline LSM (n=10), change in LSM
values #30% of baseline LSM (n=70), and LSM decreased by
.30% of baseline LSM (n=34)] [26]. no difference in LRE
development was identified (P.0.05).
Discussion
Advanced liver fibrosis or cirrhosis is significantly related to an
increased risk of hepatic decompensation and HCC development,
which, in turn, can worsen the prognosis of patients with CLD
[27]. At a time when the natural course of chronic viral hepatitis
could be observed due to the absence of antiviral agents, the
incidence of HCC in highly endemic areas was approximately 1/
100 person-years for CHB patients without cirrhosis [28,29].
Other Asian studies reported that the incidence of HCC in
untreated patients with compensated cirrhosis increased to 3–8/
100 person-years [30,31]. Moreover, the 5-year cumulative
incidence of hepatic decompensation was reported as 16–20%
(3.3–4/100 person-years) [32,33]. In our study, the incidence of
HCC and hepatic decompensation seemed relatively low (4.7/100
and 2.0/100 person-years, respectively), which can be explained in
part by the relative short follow-up period and the inclusion of
patients with F3 fibrosis stages.
However, effective antiviral agents such as NUCs and interferon
(IFN) have emerged and are actively used to prevent or delay
disease progression in patients with chronic viral hepatitis [34–36].
Hence, the natural course of chronic viral hepatitis has changed
and some recent studies have demonstrated improved prognosis in
such patients. George et al. [37] concluded that CHB patients
receiving NUCs had a significantly lower incidence of HCC
compared with untreated controls (2.4% vs. 6.4%). The regression
of liver fibrosis due to the long-term use of antiviral agents may
explain the improved long-term prognosis [38,39]. However,
because not all patients receiving antiviral treatment experience
liver fibrosis regression [40], hepatic decompensation and HCC
can eventually occur in some patients despite antiviral treatment.
Baseline HBV DNA level is the most important risk factor for
HCC development without antiviral treatment [41]. However, we
identified a significant predictive role for LSM with 19 kPa as an
optimal cutoff value when appropriate suppression of HBV DNA
using antiviral treatment was available. Similarly, Zakareya et al.
identified a significant association between LSM and the de-
velopment of cirrhosis-related complications in patients with CLD,
and concluded that LSM values .32 kPa was associated with
HCC development [42]. Because 19–32 kPa for predicting LRE
Figure 3. Box plots of LSM values in patients with F3 and F4
fibrosis stage. Median LSM value of patients with F3 and F4 were 9.0
(range, 5.7–19.8) kPa and 14.1 (range, 4.4–57.1) kPa, respectively and
LSM values in patients with F4 fibrosis stage were significantly higher
than those with F3 (10.163.7 vs. 15.868.8 kPa, P,0.001). LSM, liver
stiffness measurement; kPa, kilopascal.
doi:10.1371/journal.pone.0036676.g003
Figure 4. Incidence of LREs according to fibrosis stage and LSM
values. The incidence of LREs was similar between patients with F3
fibrosis stage and those with F4 (22.2% vs. 13.6%, P=0.472) whereas it
was signficanly different between patients with LSM value #19 kPa and
those with LSM value .19 kPa (6.9% vs. 44.4%, P,0.001). LRE, liver-
related event; LSM, liver stiffness measurement; kPa, kilopascal.
doi:10.1371/journal.pone.0036676.g004
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LSM value for cirrhosis (10.3–11.0 kPa) [43,44], it can be
postulated that cirrhosis can be further sub-classified, which
indicates that all patients with cirrhosis do not have identical
prognoses according to severity.
Because our study enrolled only patients with available histology
before starting antiviral treatment, our results cannot be directly
applied to patients who will receive antiviral treatment without
baseline LBs. However, the purpose of this study was to evaluate
the additional clinical implications of LSM value, when compared
with histologic data as a reference standard, for CHB patients
before starting antiviral treatment using NUCs. We demonstrated
that LSM with an optimal cutoff value might be useful in assessing
the risk of LRE development in these patients, which is impossible
using histologic data alone. Thus, LSM is not only a noninvasive
tool for the one-time evaluation of the degree of liver fibrosis, but
also a significant predictor of LRE development, which should be
checked before antiviral treatment regardless of LB data, in CHB
patients. Our results also suggest that LSM is more useful than LB,
and that the incidence of LREs could only be identified using
LSM, not histologic data. Since LSM values perform better than
histology, further studies investigating the predictive ability of
LSM in patients undergoing antiviral treatment using NUCs
without baseline LB data are needed.
In our study, there was a significant overlap in LSM values
between patients with F3 (5.7–19.8 kPa) and F4 (4.4–57.1 kPa),
although the overall LSM values were significantly higher in F4
fibrosis stage. This can be explained in part by the overestimating
influence of necroinflammatory activity on LSM [45]. Indeed, the
proportion of high activity (A3–4) in F3 showed a trend to be
higher than those of F4 (35.0% vs. 26.9%). Furthermore, LSM
values of patients with F3 and high activity (A3–4) was statistically
similar with those of patients with F4 and low activity (A1–2)
(mean 12.7 vs. 14.6 kPa, P.0.05). All these results might have
caused some overlapping values between patients with F3 and F4.
The prediction of LRE development using LSM was imperfect.
Although patients with baseline LSM values .19 kPa were at
a significantly greater risk of LRE development (HR, 7.176) than
were those with baseline LSM values #19 kPa, 55.6% of patients
with LSM values .19 kPa developed no LRE and 6.9% of those
with LSM values #19 kPa did. In the sub-group analysis, we
found no significant predictor of discordant results regarding LRE
development. Because this finding might be related to statistical
error due to the short-term follow-up period and the low number
of LREs, large-scale studies with long-term follow-up are needed
to elucidate a novel serological predictor of LRE development.
When we increased the sensitivity of cutoff LSM value up to
89.5%, 9.1 kPa was selected. Using this cutoff value, we can
clinically identify the sub-group of patients at low risk of LRE
development (1.6%), such that these patients can be reassured.
LSM has been known to predict fibrosis regression in response
to long-term antiviral treatment [46]. Thus, we further analyzed
the role of LSM as a dynamic indicator of LRE development using
cutoff LSM values of 19 kPa or relative change in LSM values
from baseline, but the results were negative. However, small
sample size of some groups (n=11 and 12, respectively) might be
related to type II error. Furthermore, because the study by Jung et
al. [14] revealed that LSM change, similar to baseline LSM value,
can influence HCC development, large cohorts with sufficient
events will likely be required to investigate the usefulness of serial
LSM value follow-up in patients with chronic viral hepatitis.
We included only patients with histologically advanced liver
fibrosis ($F3). However, because histologic evaluation grades liver
fibrosis categorically, it cannot exactly represent the continuous
spectrum of liver fibrosis, especially between adjacent fibrosis
grades. Furthermore, because histologic evaluation of liver fibrosis
can be influenced by intra- and interobserver variability, the over-
or underestimation of liver fibrosis inevitably occurs. Considering
these limitations of histologic evaluation, some patients who were
excluded due to F0–F2 liver fibrosis may represent under-
estimations of F3 or F4 fibrosis, which might have resulted in
selection bias, a major limitation of this study. Thus, further
validation of LSM cutoff values for predicting advanced liver
fibrosis regardless of histologic data should be performed.
Furthermore, the significantly higher proportion of patients with
F4 fibrosis may be another bias of this study.
In conclusion, our data suggest that LSM can be a useful
predictor of LRE development in CHB patients showing
histologically advanced liver fibrosis. However, this finding should
be confirmed in CHB patients without baseline histologic data
before the widespread application of LSM to all patients
undergoing antiviral treatment.
Supporting Information
Figure S1 Recruitment algorithm. A total of 178 consecu-
tive chronic hepatitis B patients were enrolled. After 50 patients
were excluded according to our exclusion criteria, a total of 128
patients were selected for statistical analysis. CHB, chronic
hepatitis B; LSM, liver stiffness measurement; LB, liver biopsy;
HCC, hepatocellular carcinoma.
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